While CAR‐T cells have shown success in B‐cell malignancies, their application in solid tumors faces challenges, including fatal toxicity from off‐target recognition (e.g., targeting ERBB2/HER2) and immunosuppressive factors in the TME that limit efficacy.[398] The high expression of EGFR in many tumor cells presents a potential target for therapeutic intervention. Here, ERBB2 is linked to neoplasm.